Snehal Patel - Greenwich Lifesciences CFO CEO

GLSI Stock  USD 11.95  0.25  2.14%   

Insider

Snehal Patel is CFO CEO of Greenwich Lifesciences
Age 62
Address Building 14, Stafford, TX, United States, 77477
Phone832 819 3232
Webhttps://greenwichlifesciences.com

Latest Insider Transactions

2025-01-10Acquired 2500 shares @ 12.51View
2025-01-07Acquired 1800 shares @ 13.75View
2025-01-02Acquired 2000 shares @ 11.97View
2024-12-30Acquired 3200 shares @ 11.12View
2024-09-26Acquired 1500 shares @ 14.63View
2024-08-05Acquired 5500 shares @ 13.18View
2024-07-23Acquired 1500 shares @ 15.89View
2024-06-13Acquired 174825 shares @ 14.3View
2024-04-01Acquired 3000 shares @ 19.08View
2024-03-22Acquired 2500 shares @ 19.98View
2024-03-20Acquired 1500 shares @ 17.68View
2024-03-04Acquired 4100 shares @ 13.03View

Snehal Patel Latest Insider Activity

Tracking and analyzing the buying and selling activities of Snehal Patel against Greenwich Lifesciences stock is an integral part of due diligence when investing in Greenwich Lifesciences. Snehal Patel insider activity provides valuable insight into whether Greenwich Lifesciences is net buyers or sellers over its current business cycle. Note, Greenwich Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Greenwich Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Greenwich Lifesciences Management Efficiency

The company has return on total asset (ROA) of (0.8985) % which means that it has lost $0.8985 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5172) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.2. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.52. As of now, Greenwich Lifesciences' Other Assets are decreasing as compared to previous years.
Greenwich Lifesciences currently holds 294.41 K in liabilities. Greenwich Lifesciences has a current ratio of 64.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Greenwich Lifesciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jason CPAMediciNova
47
Mary DiBiaseX4 Pharmaceuticals
64
Liean MSAcumen Pharmaceuticals
N/A
Kerry MDTerns Pharmaceuticals
N/A
CPA CPAAnavex Life Sciences
41
Shauna HorvathAmylyx Pharmaceuticals
N/A
Charles IIDay One Biopharmaceuticals
47
Yuichi MDMediciNova
75
Matthew CPAPDS Biotechnology Corp
55
Michael MSBANextCure
64
MBA MSAnavex Life Sciences
56
Gina MazzarielloAmylyx Pharmaceuticals
53
CPA CPAAcurx Pharmaceuticals LLC
58
Chris AielloAmylyx Pharmaceuticals
N/A
PharmD ChiodinDay One Biopharmaceuticals
N/A
Timothy MayerNextCure
60
Hillel MBAEntera Bio
47
Miranda MBAEntera Bio
48
Walter MDAnavex Life Sciences
N/A
Tom HolmesAmylyx Pharmaceuticals
N/A
Lauren MDPDS Biotechnology Corp
64
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. Greenwich Lifesciences (GLSI) is traded on NASDAQ Exchange in USA. It is located in Building 14, Stafford, TX, United States, 77477 and employs 3 people. Greenwich Lifesciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Greenwich Lifesciences Leadership Team

Elected by the shareholders, the Greenwich Lifesciences' board of directors comprises two types of representatives: Greenwich Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Greenwich. The board's role is to monitor Greenwich Lifesciences' management team and ensure that shareholders' interests are well served. Greenwich Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Greenwich Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Snehal Patel, CFO CEO
Eric Rothe, Founder Director
Frank MD, Chief Director
Jaye Thompson, Vice Affairs
Christine Fischette, VP Development

Greenwich Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Greenwich Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Return On Assets
(0.90)
Return On Equity
(1.52)
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.